News
70 or Older? 3 Stocks You Should Consider Buying
Investment priorities naturally evolve as we age. For investors in their 70s, stability and income should be prioritized over growth and capital appreciation potential. That's why companies like....
70 or Older? 3 Stocks You Should Consider Buying
Investment priorities naturally evolve as we age. For investors in their 70s, stability and income should be prioritized over growth and capital appreciation potential. That's why companies like....
4 of the Highest-Growth Stocks in Biotech Today
Investing in the biotech industry can be a risky business. In most instances, the deck is stacked against a company succeeding. The vast majority of preclinical studies will fail to reach human....
4 of the Highest-Growth Stocks in Biotech Today
Investing in the biotech industry can be a risky business. In most instances, the deck is stacked against a company succeeding. The vast majority of preclinical studies will fail to reach human....
Why Stryker, Ultragenyx Pharmaceutical, and La-Z-Boy Slumped Today
Major benchmarks trended downward Wednesday, taking a break from the rally that had boosted stocks in the previous session. Investors seemed uncertain about President Donald Trump's plans to....
Why Ultragenyx Pharmaceutical Stock Is Sinking Today
Shares of the rare-disease drugmaker Ultragenyx Pharmaceutical (NASDAQ: RARE) are under pressure today after the company announced that its late-stage study assessing aceneuramic acid extended....
Here's Why Paratek Pharmaceuticals Soared as Much as 37% Today
Shares of clinical-stage biopharma Paratek Pharmaceuticals (NASDAQ: PRTK) soared 37% today after news leaked that the company is considering a sale.The stock has returned solid gains to investors....
2 Marijuana Stocks That Have Imploded Since August Began
In many ways, the legal marijuana industry could be described as the greatest thing since sliced bread for investors. Over the trailing one-year period, the average marijuana stock has increased....
3 Reasons AbbVie Is a Better Dividend Stock Than Gilead Sciences
Gilead Sciences (NASDAQ: GILD) claims one of the top-selling drugs in the world with Harvoni. But AbbVie (NYSE: ABBV) markets the best-selling drug in the world -- Humira. Gilead Sciences is one....
How Johnson & Johnson Makes Most of Its Money
As you might expect, Johnson & Johnson (NYSE: JNJ) makes a lot of money. Last year, the healthcare giant generated revenue totaling nearly $72 billion. Over the past decade, J&J raked in....
How Johnson & Johnson Makes Most of Its Money
As you might expect, Johnson & Johnson (NYSE: JNJ) makes a lot of money. Last year, the healthcare giant generated revenue totaling nearly $72 billion. Over the past decade, J&J raked in....
3 Reasons AbbVie Is a Better Dividend Stock Than Gilead Sciences
Gilead Sciences (NASDAQ: GILD) claims one of the top-selling drugs in the world with Harvoni. But AbbVie (NYSE: ABBV) markets the best-selling drug in the world -- Humira. Gilead Sciences is one....
3 Reasons AbbVie Is a Better Dividend Stock Than Gilead Sciences
Gilead Sciences (NASDAQ: GILD) claims one of the top-selling drugs in the world with Harvoni. But AbbVie (NYSE: ABBV) markets the best-selling drug in the world -- Humira. Gilead Sciences is one....
What's Next for Bristol-Myers Squibb After Its Opdivo Setback?
The signs were definitely there for a disappointment from Bristol-Myers Squibb (NYSE: BMY). Several weeks ago, AstraZeneca (NYSE: AZN) reported its checkpoint inhibitor Imfinzi failed to improve....
What's Next for Bristol-Myers Squibb After Its Opdivo Setback?
The signs were definitely there for a disappointment from Bristol-Myers Squibb (NYSE: BMY). Several weeks ago, AstraZeneca (NYSE: AZN) reported its checkpoint inhibitor Imfinzi failed to improve....
What's the Most Important Drug in Regeneron Pharmaceuticals' Pipeline?
Regeneron Pharmaceuticals (NASDAQ: REGN) has four significant medications on the market, including three that have won Food and Drug Administration approval since 2015, and it's investing big....
What's the Most Important Drug in Regeneron Pharmaceuticals' Pipeline?
Regeneron Pharmaceuticals (NASDAQ: REGN) has four significant medications on the market, including three that have won Food and Drug Administration approval since 2015, and it's investing big....
What's the Most Important Drug in Regeneron Pharmaceuticals' Pipeline?
Regeneron Pharmaceuticals (NASDAQ: REGN) has four significant medications on the market, including three that have won Food and Drug Administration approval since 2015, and it's investing big....
What Will Drive Regeneron Pharmaceuticals' Growth Higher From Here?
Regeneron Pharmaceuticals' (NASDAQ: REGN) $5 billion in sales in 2016 were due mostly to sales of its top-selling vision-restoring drug Eylea. However, a slate of newly Food and Drug....
What Will Drive Regeneron Pharmaceuticals' Growth Higher From Here?
Regeneron Pharmaceuticals' (NASDAQ: REGN) $5 billion in sales in 2016 were due mostly to sales of its top-selling vision-restoring drug Eylea. However, a slate of newly Food and Drug....
What Will Drive Regeneron Pharmaceuticals' Growth Higher From Here?
Regeneron Pharmaceuticals' (NASDAQ: REGN) $5 billion in sales in 2016 were due mostly to sales of its top-selling vision-restoring drug Eylea. However, a slate of newly Food and Drug....
Why Eylea Is Still Regeneron Pharmaceuticals' Most Important Drug
Aging baby boomers are turning 65 years old at a pace of 10,000 per day, and that's causing an increase in the diagnosis of common causes of vision loss, including age-related macular degeneration....
Why Eylea Is Still Regeneron Pharmaceuticals' Most Important Drug
Aging baby boomers are turning 65 years old at a pace of 10,000 per day, and that's causing an increase in the diagnosis of common causes of vision loss, including age-related macular degeneration....
Why Eylea Is Still Regeneron Pharmaceuticals' Most Important Drug
Aging baby boomers are turning 65 years old at a pace of 10,000 per day, and that's causing an increase in the diagnosis of common causes of vision loss, including age-related macular degeneration....
3 Top Stocks Under $5
Tiny stocks don't get a lot of love on Wall Street -- and by tiny I mean companies that have a share price of under $5. According to the Securities and Exchange Commission, any stock that trades....